ABSTRACT
Objectives To determine the impact of dopamine deficiency and isolated REM sleep behavior disorder (iRBD) on cognitive performance in early neuronal alpha-synuclein disease (NSD) with hyposmia.
Methods Using Parkinson’s Progression Markers Initiative baseline data, cognitive performance was assessed with a cognitive summary score (CSS) developed by applying regression-based internal norms derived from a robust healthy control (HC) group. Performance was examined for participants with hyposmia classified as NSD-Integrated Staging System (NSD-ISS) Stage 2, either Stage 2A (CSF alpha-synuclein seed amplification assay [SAA]+, SPECT dopamine transporter scan [DaTscan]-) or 2B (SAA+, DaTscan+).
Results Participants were Stage 2A (N=101), Stage 2B (N=227) and HCs (N=158). Although Stage 2 overall had intact Montreal Cognitive Assessment scores (mean (SD) =27.0 (2.3)), Stage 2A had a numerically worse CSS (z-score mean difference =0.05, p-value NS; effect size=0.09) and Stage 2B had a statistically worse CSS (z-score mean difference =0.23, p-value <0.05; effect size=0.40) compared with HCs. In Stage 2A participants with hyposmia alone had normal cognition, but presence of comorbid iRBD was associated with significantly worse cognition (z-score mean difference =0.33, p-value <0.05, effect size =0.50). In Stage 2B participants with hyposmia had abnormal cognition (z-score mean difference =0.18, p-value =.0078, effect size =0.29), and superimposed iRBD had a non-statistically significant additive effect.
Interpretation Using a CSS, early NSD with hyposmia is associated with measurable cognitive deficits compared with robust HCs, particularly in presence of dopamine system impairment or comorbid iRBD, highlighting the importance of focusing on cognition in early-stage synuclein disease.
Competing Interest Statement
DW declares grant support to his institution from the Michael J. Fox Foundation for Parkinson's Research. AN declares research funding to her institution from The Michael J. Fox Foundation. RK declares research funding to his institution from The Michael J. Fox Foundation. MB declares travel grants from The Michael J. Fox Foundation. Receives grant support to her institution from the Michael J. Fox Foundation for Parkinson's Research. MY declares consultancies for Blue Rock Therapeutics and The Michael J. Fox Foundation. Receives grant support to her institution from the Michael J. Fox Foundation for Parkinson's Research and the VA Office of Rural Health. KMa declares support to his institution (Institute for Neurodegenerative Disorders) from The Michael J. Fox Foundation. KM also declares consultancies for Invicro, The Michael J. Fox Foundation, Roche, Calico, Coave, Neuron23, Orbimed, Biohaven, Anofi, Koneksa, Merck, Lilly, Inhibikase, Neuramedy, IRLabs and Prothena and participates on DSMB at Biohaven. CT declares consultancies for CNS Ratings, Australian Parkinson's Mission, Biogen, Evidera, Cadent (data safety monitoring board), Adamas (steering committee), Biogen (via the Parkinson Study Group steering committee), Praxis (via the International Parkinsons and Movement Disorder Society), Kyowa Kirin (advisory board), Lundbeck (advisory board), Jazz/Cavion (steering committee), Acorda (advisory board), Bial (DMC) and Genentech. CT also declares grant support to her institution from The Michael J. Fox Foundation, National Institute of Health, Gateway LLC, Department of Defense, Roche Genentech, Biogen, Parkinson Foundation and Marcus Program in Precision Medicine. CT declares membership on the npj Parkinson's Disease Editorial Board. TSi declares consultancies for AcureX, Adamas, AskBio, Amneal, Blue Rock Therapeutics, Critical Path for Parkinson's Consortium, Denali, The Michael J. Fox Foundation, Neuroderm, Roche, Sanofi, Sinopia, Takeda, and Vanqua Bio; on advisory boards for AcureX, Adamas, AskBio, Biohaven, Denali, GAIN, Neuron23 and Roche; on scientific advisory boards for Koneksa, Neuroderm, Sanofi and UCB; and received research funding from Amneal, Biogen, Roche, Neuroderm, Sanofi, Prevail and UCB and an investigator for NINDS, MJFF, Parkinson's Foundation. AS declares consultancies for Mitsubishi, GE healtcare, Capsida Therapeutics and Parkinson Study Group; grants from The Michael J. Fox Foundation (member of PPMI Steering Committee); and participation on DSMB boards at Spark Therapeutics, Cerevance. Alerity, Wave Life Sciences, Inhibikase, Prevai (Eli Lilly), Huntington Study Group and Massachusetts General Hospital. DG has nothing to declare. LC declares grants to her institution from Biogen (clinical trial funding), MJFF, UPMC Competitive Medical Research Fund, National Institutes of Health, and University of Pittsburgh; grant and travel support from MJFF; royalties from Wolters Kluwel (for authorship); and in-kind donation by Advanced Brain Monitoring of equipment for research study to her institution. CC declares grants from The Michael J. Fox Foundation and NIH/NINDS. KMe declares consultancies for The Michael J. Fox Foundation, Calico Labs, HanAll Biopharma, Janssen Pharmaceuticals, NRG Therapeutics (scientific advisory board), Nitrase Therapeutics (scientific advisory board), Nurabio, Retromer Therapeutics (director on the board, part-time chief scientific officer), Rome Therapeutics, Schrodinger, Sinopia Biosciences (scientific advisory board), and Vanqua Biosciences (scientific advisory board), Ventyx Biosciences; stock ownership for Cognition Therapeutics, Eli Lilly (retiree stock holder), Envisagenics, Nitrase Therapeutics, NuraBio, Sinopia Biosciences and Retromer Therapeutics; honoraria for the University of Utah, ASAP; patents or patent applications for Retromer Therapeutics; research grant from The Michael J. Fox Foundation and travel grants from the University of Utah, ASAP, Michael J Fox Foundation, Northwestern University. KP declares consultancies for Curasen, Novartis, Biohaven and Neuron23; was on a scientific advisory board for Curasen and Amprion; and patents or patent applications numbers 17/314,979 and 63/377,293. KP also declares grants to her institution (Stanford University School of Medicine) from NIH (U19 AG065156, R01 NS107513, R01 NS115114, P30 AG066515, R01 AG081144, R21 NS132101, U01 DK140939, R01 AG089169), Michael J Fox Foundation for Parkinson's Research, the Knight Initiative for Brain Resilience, the Wu Tsai Neuroscience Institute, Lewy Body Dementia Association, Alzheimer's Drug Discovery Foundation and the Sue Berghoff LBD Research Fellowship. TF declares travel grants and grant payments to her institution (Indiana University) from The Michael J. Fox Foundation. BM declares consultancies from Roche and Biogen; grants from The Michael J. Fox Foundation, ASAP and DFG; honoraria for Abbvie and Bial; leadership role for The Michael J. Fox Foundation and travel grants for Abbvie. EB declares consultancies from Guidepoint Inc, a role on a scientific advisory board for 53Therapeutics, grants from the Michael J. Fox Foundation, the Department of Defense, the NIH, and Gateway Institute for Brain Research, Inc. KK declares support to his institution from The Michael J. Fox Foundation. MF declares employment for and travel grants from The Michael J. Fox Foundation. TS declares employment for and travel grants from The Michael J. Fox Foundation. TSh has nothing to declare. SC declares employment for and travel grants from The Michael J. Fox Foundation. RA declares grants to his institution research from the Michael J. Fox Foundation, the Silverstein Foundation and the Parkinson's Foundation. He received consultation fees from Biogen, Biohaven, Capsida, Gain Therapeutics, Genzyme/Sanofi, Janssen, Servier, SK Biopharmaceuticals, Takeda and Vanqua Bio. AV declares research support by NIH: NS077179, NS129636, DK140921, NS114001, AG063982, and The Michael J. Fox Foundation.
Funding Statement
PPMI, a public-private partnership, is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, BioArctic, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Capsida Biotherapeutics, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Jazz Pharmaceuticals, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Neuron23, Neuropore, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data used in the preparation of this article were obtained on February 05, 2024, from the PPMI database (www.ppmi-info.org/access-data-specimens/download-data), RRID:SCR_006431. For up-to-date information on the study, visit www.ppmi-info.org. The analyses were conducted by the PPMI Statistics Core and used actual dates of activity for participants, a restricted data element not available to public users of PPMI data. The PPMI Data Access Committee approved use of the α-syn SAA and DaTscan results for participants. Statistical analysis codes used to perform the analyses in this article are shared on Zenodo [10.5281/zenodo.14047599]. Information about the PPMI protocol can be found on protocols.io: https://dx.doi.org/10.17504/protocols.io.n92ldmw6ol5b/v2
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos